Loading...
XTAI
4746
Market cap205mUSD
Jul 09, Last price  
54.80TWD
1D
-1.97%
1Q
6.61%
Jan 2017
-44.93%
IPO
-41.05%
Name

Formosa Laboratories Inc

Chart & Performance

D1W1MN
XTAI:4746 chart
P/E
14.94
P/S
1.36
EPS
3.67
Div Yield, %
5.47%
Shrs. gr., 5y
-1.80%
Rev. gr., 5y
9.54%
Revenues
4.85b
+2.54%
02,505,914,0002,625,647,0002,524,282,0002,473,633,0002,496,224,0002,596,722,0003,189,380,0002,539,353,0002,687,731,0002,759,591,0003,075,457,0003,142,406,0003,765,504,0004,360,448,0004,731,046,0004,851,357,000
Net income
441m
+180.48%
0246,621,000231,067,0005,003,000-69,401,000262,495,000282,392,000483,441,000238,645,000176,821,000-41,062,000400,034,0001,249,096,000216,810,000126,243,000157,268,000441,107,000
CFO
1.32b
+81.08%
099,671,000-11,231,000171,135,00032,253,000280,408,000255,149,0001,110,075,000395,419,000-80,894,000289,924,000475,004,000311,157,000643,086,000826,600,000726,334,0001,315,247,000
Dividend
Aug 21, 20253 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulators, respiratory agents, cholesterol and phosphate binders, UV filter, iron deficiency anemia (IDA), CNS agents, MRI enhancing agents, steroids, antibiotics, and other areas; and injectables in the areas of IDA, MRI agents, oncology, and others. The company also provides contract development and manufacturing services, including recrystallization, filtration, dialysis, column purification, distillation, spray drying, and micronization; injectable manufacturing and secondary packaging, labeling, and serialization services; custom fermentation services; and peptide synthesis services. In addition, it offers antibody-drug conjugates services comprising antibody development and manufacture; peptide and polymer drug conjugation; linker-payload design, synthesis, and manufacturing; bio-conjugation and purification; cytotoxic liquid-filled and lyophilized product from pre-formulation studies to manufacture; and regulatory support. Further, the company is involved in chemical trading and investment activities. Formosa Laboratories, Inc. was incorporated in 1985 and is headquartered in Taoyuan City, Taiwan.
IPO date
Nov 27, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT